Activin and myostatin are growth factors that belong to the TGF-β superfamily, and they are known to have negative effects on muscle and bone mass [108, 109]; therefore, their downregulation might be considered a therapeutic approach to prevent muscle wasting and bone degeneration in DMD patients [71]. This evidence concerns the gene MSTN and Duchenne muscular dystrophy.